- Home
- RIGL vs LE Comparison
RIGL vs LE Comparison
Compare RIGL & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- LE
- Stock Information
- Founded
- RIGL 1996
- LE 1963
- Country
- RIGL United States
- LE United States
- Employees
- RIGL N/A
- LE N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- LE Clothing/Shoe/Accessory Stores
- Sector
- RIGL Health Care
- LE Consumer Discretionary
- Exchange
- RIGL Nasdaq
- LE Nasdaq
- Market Cap
- RIGL 486.4M
- LE 404.6M
- IPO Year
- RIGL 2000
- LE N/A
- Fundamental
- Price
- RIGL $17.09
- LE $13.07
- Analyst Decision
- RIGL Buy
- LE Strong Buy
- Analyst Count
- RIGL 5
- LE 2
- Target Price
- RIGL $34.80
- LE $20.00
- AVG Volume (30 Days)
- RIGL 203.8K
- LE 173.8K
- Earning Date
- RIGL 11-07-2024
- LE 12-05-2024
- Dividend Yield
- RIGL N/A
- LE N/A
- EPS Growth
- RIGL N/A
- LE N/A
- EPS
- RIGL 0.22
- LE N/A
- Revenue
- RIGL $157,374,000.00
- LE $1,436,124,000.00
- Revenue This Year
- RIGL $48.98
- LE N/A
- Revenue Next Year
- RIGL $14.43
- LE $2.01
- P/E Ratio
- RIGL $77.18
- LE N/A
- Revenue Growth
- RIGL 21.65
- LE N/A
- 52 Week Low
- RIGL $7.48
- LE $7.64
- 52 Week High
- RIGL $29.82
- LE $19.88
- Technical
- Relative Strength Index (RSI)
- RIGL 30.82
- LE 34.07
- Support Level
- RIGL $16.68
- LE $12.86
- Resistance Level
- RIGL $19.80
- LE $14.62
- Average True Range (ATR)
- RIGL 1.53
- LE 0.79
- MACD
- RIGL -1.05
- LE -0.19
- Stochastic Oscillator
- RIGL 3.66
- LE 5.45
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.